Reimbursed Care Access in Germany

Psilocybin is not a routinely reimbursed, authorised treatment in Germany and remains a controlled substance under Germany’s narcotics framework; clinical access is therefore normally limited to authorised clinical trials and regulated special programmes. The Federal Institute for Drugs and Medical Devices (BfArM) maintains the regulatory framework for clinical trials and for exceptional access schemes in Germany #.

There is an actively listed compassionate‑use / Härtefall (hardship) programme for psilocybin in Germany: an entry on the BfArM compassionate‑use table shows a confirmed programme for 'Psilocybin bei therapieresistenter Depression' with a listed start of 11.07.2025 and a one‑year duration through 11.07.2026 (responsible centre: Zentralinstitut für Seelische Gesundheit, Mannheim). This indicates limited, regulated non‑market access for a defined patient group under a hardship programme rather than routine market authorisation or broad statutory health insurance reimbursement #.

Practical consequences: access is therefore (a) within regulated clinical trials authorised by BfArM/ethics committees, or (b) via narrowly defined compassionate‑use/hardship programmes that are time‑limited and site‑specific. These programmes do not constitute general reimbursement entitlement by statutory health insurance (GKV) and require adherence to the programme’s inclusion criteria and oversight by the responsible clinical centre #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Esketamine (marketed as Spravato®) is an authorised medicine in the EU and is approved for adults with treatment‑resistant major depressive disorder in combination with an SSRI or SNRI; the EMA product information describes administration as a supervised nasal spray in a clinic or doctor’s office and specifies the licensed indication and monitoring requirements #.

In Germany the Gemeinsame Bundesausschuss (G‑BA) has evaluated esketamine under national benefit‑assessment procedures and published decisions and supporting dossiers: G‑BA materials note that Spravato became verordnungsfähig in Germany from 1 March 2021 for adults with treatment‑resistant major depression (in combination with SSRI/SNRI) and that the G‑BA has undertaken subsequent benefit‑assessment proceedings (including a re‑assessment concluding in 2023) relevant to reimbursement and the Arzneimittel‑Richtlinie framework # #.

Reimbursement and prescribing constraints: because Spravato is an authorised medicinal product and has been the subject of the G‑BA's Nutzenbewertung, its use is regulated—prescription is restricted to psychiatrists and administration must occur under medical supervision (clinic/office setting). The G‑BA decision process determines the framework for statutory health insurance (GKV) coverage or limitation conditions; as an authorised product with G‑BA proceedings completed, Esketamine is available within the regulated reimbursement system subject to the G‑BA's specifications and any conditions defined in the Arzneimittel‑Richtlinie and benefit assessment documents #.

Safety/supervision obligations: the EMA and G‑BA materials both stress supervised administration and monitoring (e.g., blood pressure checks and availability of resuscitation facilities as indicated by the EMA) and national pharmacovigilance reporting; the BfArM has also highlighted the need to monitor the risk of misuse/abuse of ketamine‑class medicines in Germany in recent committee reporting # #.

Ketamine is an authorised anaesthetic/analgesic agent in Germany (ATC classification N01AX03) and is used widely in anaesthesia and emergency medicine; its use as a psychiatric (antidepressant) agent is considered off‑label in the treatment of depressive disorders. The ATC/DDD listing and national product classifications recognise ketamine for clinical use in anaesthesia #.

Off‑label psychiatric use and reimbursement: the use of intravenous ketamine for depression or suicidality is off‑label in Germany and therefore sits outside a standard marketing authorisation for that indication; clinical guidance and G‑BA documentation explicitly note that i.v. ketamine for depressive disorders is off‑label and that evidence is still evolving, with potential legal and reimbursement implications for prescribers and patients #. The BfArM has also signalled attention to the risk of misuse of ketamine‑containing medicinal products and reports that a substantial proportion of ketamine dispensing was on private prescriptions, underscoring the limited routine reimbursement pathways for non‑authorised psychiatric indications #.

Operational implications: when ketamine is used for psychiatric indications in Germany it is typically provided in specialised hospital or clinic settings under physician supervision, and reimbursement (statutory or private) depends on the treatment setting, billing pathway and whether use can be justified within established legal/medical frameworks. Because this is off‑label use, prescribers should follow applicable regional rules, document clinical rationale and obtain informed consent; routine GKV coverage is not guaranteed for off‑label psychiatric use absent specific G‑BA/health‑insurer decisions.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (Note: ceremonial/ritual use does not confer medical authorisation; any use is subject to BtMG controls and public‑health/regulatory oversight.) #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (Mescaline and related phenethylamines are listed among psychodysleptics in national coding/classification material.) # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 2C‑series phenethylamine derivatives are routinely addressed in the narcotics scheduling and expert committee processes maintained by BfArM and the Federal Opium Agency # #.